Vanguard Group’s Yield10 Bioscience, Inc. Common Stock YTEN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-1,685
Closed -$15.4K 4492
2024
Q1
$15.4K Hold
1,685
﹤0.01% 4408
2023
Q4
$9.68K Hold
1,685
﹤0.01% 4479
2023
Q3
$13.2K Sell
1,685
-2,768
-62% -$69.7K ﹤0.01% 4515
2023
Q2
$237K Hold
4,453
﹤0.01% 4284
2023
Q1
$295K Buy
4,453
+142
+3% +$10.3K ﹤0.01% 4253
2022
Q4
$173K Buy
4,311
+4
+0.1% +$238 ﹤0.01% 4332
2022
Q3
$309K Sell
4,307
-458
-10% -$30.9K ﹤0.01% 4338
2022
Q2
$257K Sell
4,765
-110
-2% -$7.77K ﹤0.01% 4433
2022
Q1
$620K Hold
4,875
﹤0.01% 4344
2021
Q4
$576K Hold
4,875
﹤0.01% 4404
2021
Q3
$701K Buy
4,875
+66
+1% +$11.1K ﹤0.01% 4322
2021
Q2
$985K Buy
4,809
+1,577
+49% +$351K ﹤0.01% 4149
2021
Q1
$972K Buy
+3,232
New +$1.09M ﹤0.01% 4016
2020
Q1
Sell
-108
Closed -$18K 4102
2019
Q4
$18K Hold
108
﹤0.01% 4095
2019
Q3
$52K Hold
108
﹤0.01% 4083
2019
Q2
$98K Hold
108
﹤0.01% 4051
2019
Q1
$118K Hold
108
﹤0.01% 3999
2018
Q4
$86K Hold
108
﹤0.01% 4014
2018
Q3
$147K Hold
108
﹤0.01% 4042
2018
Q2
$146K Buy
108
+39
+57% +$61.8K ﹤0.01% 4019
2018
Q1
$129K Buy
+69
New +$117K ﹤0.01% 4011
2017
Q2
Sell
-1
Closed -$4K 4086
2017
Q1
$4K Hold
1
﹤0.01% 4067
2016
Q4
$4K Sell
1
-7
-88% -$26.9K ﹤0.01% 4076
2016
Q3
$35K Sell
8
-3
-27% -$15.2K ﹤0.01% 4053
2016
Q2
$88K Hold
11
﹤0.01% 4036
2016
Q1
$201K Hold
11
﹤0.01% 3961
2015
Q4
$163K Buy
11
+1
+10% +$20.2K ﹤0.01% 4032
2015
Q3
$134K Hold
10
﹤0.01% 4070
2015
Q2
$365K Hold
10
﹤0.01% 3945
2015
Q1
$349K Buy
10
+1
+11% +$32K ﹤0.01% 3909
2014
Q4
$215K Hold
9
﹤0.01% 3893
2014
Q3
$490K Sell
9
-1
-10% -$43.2K ﹤0.01% 3716
2014
Q2
$477K Hold
10
﹤0.01% 3694
2014
Q1
$713K Buy
10
+2
+25% +$158K ﹤0.01% 3557
2013
Q4
$603K Hold
8
﹤0.01% 3544
2013
Q3
$603K Hold
8
﹤0.01% 3505
2013
Q2
$679K Buy
+8
New +$773K ﹤0.01% 3405

Vanguard Group's YTEN Position: Q2 2024 in Review

Vanguard Group sold out of Yield10 Bioscience, Inc. Common Stock (YTEN) in Q2 2024, closing a stake of 1,685 shares — an estimated $15.4K sold.

Vanguard Group first reported a position in YTEN in Q2 2013 and held it in 37 quarters. The position peaked at $985K in Q2 2021. 0 funds tracked by Wall St. Rank hold YTEN as of Q2 2024.

  • Vanguard Group reported no remaining Yield10 Bioscience, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Vanguard Group sold 1,685 Yield10 Bioscience, Inc. Common Stock shares in Q2 2024, an estimated $15.4K.
  • Vanguard Group first reported a position in Yield10 Bioscience, Inc. Common Stock in Q2 2013 and held it in 37 quarters.
  • Vanguard Group's Yield10 Bioscience, Inc. Common Stock position peaked at $985K in Q2 2021.
  • 0 funds tracked by Wall St. Rank held Yield10 Bioscience, Inc. Common Stock as of Q2 2024.

Based on Vanguard Group's 13F filing for Q2 2024, filed 13 Aug 2024.